Zimmer Biomet Holdings Inc (ZBH) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.

Total Cash From Operating Activities Chart for Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings Inc (ZBH) operating cash flow for FY2025 was USD 1.7B, a 13.2% change from FY2024. Zimmer Biomet Holdings Inc's operating cash flow grew from USD 199.0M in 1998 to USD 1.7B in 2025 (752.8% over 27 years). Operating cash flow compound annual growth rate: 5-year CAGR of 7.1%, 10-year CAGR of 7.2%, 20-year CAGR of 3.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$18.54B
Implied Share Price
$97.19
Enterprise Value
$26.06B
Revenue (TTM)
$8.51B
EBITDA
$2.56B
Profit Margin
9.48%
Trailing P/E
23.82
Forward P/E
11.47
Price/Book (MRQ)
1.46
Price/Sales (TTM)
2.18
EV/EBITDA
11.08
EV/Revenue
3.04
Dividend Yield
0.49%
Book Value
$65.73
Free Cash Flow (FY2025)
$1.47B
Free Cash Flow Yield
7.94%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.